BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 14562125)

  • 21. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Real-time PCR array for simultaneous detection of 37 kinds of fusion genes in leukemia].
    Liu HX; Zhu P; Zhang Y; Wang HX; DU JW; Liu J; Gu JY; Ou Y
    Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):526-32. PubMed ID: 17459201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
    Willasch AM; Gruhn B; Coliva T; Kalinova M; Schneider G; Kreyenberg H; Steinbach D; Weber G; Hollink IH; Zwaan CM; Biondi A; van der Velden VH; Reinhardt D; Cazzaniga G; Bader P; Trka J;
    Leukemia; 2009 Aug; 23(8):1472-9. PubMed ID: 19322206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
    Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
    Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular responses in acute promyelocytic leukemia patients monitored by real-time quantitative RT-PCR].
    Yao L; Chen ZX; Cen JN
    Ai Zheng; 2008 Feb; 27(2):214-7. PubMed ID: 18279625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The significance of minimal residual disease in patients with t(15;17).
    Grimwade D
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):137-58. PubMed ID: 11987921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.
    van der Velden VH; Panzer-Grümayer ER; Cazzaniga G; Flohr T; Sutton R; Schrauder A; Basso G; Schrappe M; Wijkhuijs JM; Konrad M; Bartram CR; Masera G; Biondi A; van Dongen JJ
    Leukemia; 2007 Apr; 21(4):706-13. PubMed ID: 17287857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplex RT-PCR assay for the detection of major fusion transcripts in Taiwanese children with B-lineage acute lymphoblastic leukemia.
    Liang DC; Shih LY; Yang CP; Hung IJ; Chen SH; Jaing TH; Liu HC; Chang WH
    Med Pediatr Oncol; 2002 Jul; 39(1):12-7. PubMed ID: 12116073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
    Brüggemann M; Gökbuget N; Kneba M
    Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-time quantitative reverse transcriptase polymerase chain reaction.
    Fan H; Robetorye RS
    Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a NanoString assay to detect leukemogenic fusion transcripts in acute myeloid leukemia.
    Hu D; Zhou W; Wang F; Shu SM; Fan LL; He J; Wang P; He YL; Du W; Zhang JH; Duan JX; Sun L; Zheng J; Li XQ; Li HY; Feng XL; Huang SA
    Int J Lab Hematol; 2016 Dec; 38(6):663-673. PubMed ID: 27460049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
    Müller MC; Hördt T; Paschka P; Merx K; La Rosée P; Hehlmann R; Hochhaus A
    Acta Haematol; 2004; 112(1-2):30-3. PubMed ID: 15179002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
    Weisser M; Haferlach C; Haferlach T; Schnittger S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
    Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
    Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results].
    Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K
    Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.